Worth reading
71In focus
Scored from 4 of 5 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
38.3
% (change in ordinary profit)Wording
Avoiding a definitive answer
How definitive the wording is.Revised forecast
2024 年 3 月期 · Full yearPrevious forecast published 2023 年 5 月 15 日発表Net Sales13,500→12,930million
-4.2%
Operating profit840→1,110million
+32.1%
Ordinary income810→1,120million
+38.3%
Profit attributable to owners of the parent600→740million
+23.3%
Net income per share—→—yen
—
The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Reason for the revision
半導体関連材料の一部製品の需要低迷で売上高は減少したが、円安の影響、電子材料向け新製品、主に海外で展開している原薬の販売拡大、経費の節減などにより各段階利益は増加した。
Previous-period results2023 年 3 月期：売上高12,839百万円、営業利益897百万円、経常利益660百万円、当期純利益556百万円、1株当たり当期純利益25円51銭
Dividend forecast revision期末配当を1株当たり7円から8円へ1円増額。年間配当は7円から8円へ修正。
| Item | Details |
|---|---|
| Net Sales | ¥13,500 million → ¥12,930 million（△4.2％） |
| Operating profit | ¥840 million → ¥1,110 million（32.1％） |
| Ordinary income | ¥810 million → ¥1,120 million（38.3％） |
| Profit attributable to owners of the parent | ¥600 million → ¥740 million（23.3％） |
| Net income per share | 27 円 49 銭 → ¥34.00 |
| Fiscal Period Covered | 2024 年 3 月期 |
| Period Covered | Full year |
| Publication date of previous forecast | 2023 年 5 月 15 日発表 |
| Previous-period results | 2023 年 3 月期：売上高12,839百万円、営業利益897百万円、経常利益660百万円、当期純利益556百万円、1株当たり当期純利益25円51銭 |
| Reason for the revision | 半導体関連材料の一部製品の需要低迷で売上高は減少したが、円安の影響、電子材料向け新製品、主に海外で展開している原薬の販売拡大、経費の節減などにより各段階利益は増加した。 |
| Dividend forecast revision | 期末配当を1株当たり7円から8円へ1円増額。年間配当は7円から8円へ修正。 |
Items this document does not state (2)
Details and amount of extraordinary lossConsolidated / non-consolidated
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.半導体関連材料の一部製品の需要低迷により売上高は減少した。一方、円安の影響、電子材料向け新製品、主に海外で展開している原薬の販売拡大、経費の節減などにより、各段階利益は増加した。配当は、業績予想の修正、直近の財務状況、今後の経営環境などを総合的に判断して増額した。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.